Eco Animal Health (EAH) AI Stock Analysis

• Market Cap: £65.39M
• Dividend Yield: N/A
• Average Volume (3M): 75.04K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.93
• Revenue Growth: 1.44%
• EPS Growth: 359.79%
• Country: UK
• Employees: 227
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 67,759,674
• 10 Day Avg. Volume: 57,390
• 30 Day Avg. Volume: 75,042
• PEG Ratio: 0.35
• Price to Book (P/B): 0.42
• Price to Sales (P/S): 0.45
• P/FCF Ratio: 6.65
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 0.03
• Revenue Forecast (FY): £83.58M

• Rating: 76 Outperform
• Price Target: 109.00 p ▲(38.85% Upside)
• Action: Reiterated Date: 12/07/25
• Date: Action: Reiterated 12/07/25

Eco Animal Health's overall stock score is driven by strong technical momentum and positive corporate events, indicating confidence in future growth. However, the high valuation and inconsistent financial performance temper the score, suggesting potential risks if growth expectations are not met.

Positive Factors

Strong balance sheet and low leverage

Conservative leverage and a healthy equity ratio provide durable financial flexibility. This allows the company to fund regulatory registrations, R&D and selective commercial rollouts without overreliance on external debt, lowering refinancing and solvency risks over the medium term.

Improving free cash flow generation

Rising free cash flow strengthens self-funding capacity for product launches, marketing and incremental M&A. Sustainable FCF reduces the need for dilutive equity or costly debt, supporting long-term investment in registrations and international commercialization.

R&D progress and management alignment

Management share purchases and visible R&D milestones signal alignment and de‑risking of the pipeline. Successful AGM resolutions and H1 results suggest governance stability, which supports sustained product approvals and partner deals that underpin long-term revenue potential.

Negative Factors

Inconsistent revenue growth; recent decline

Volatile and recently declining revenues reduce predictability for investment and capacity planning. For a specialty animal‑health firm reliant on approvals and regional rollouts, inconsistent top-line trends increase execution risk and make multi‑period forecasting and margin expansion harder.

Low and declining profitability margins

Declining gross margins and low net margins limit the firm's ability to absorb rising input or regulatory costs and reduce retained earnings for reinvestment. Structural margin pressure weakens long‑term earnings resilience versus competitors and constrains strategic flexibility.

Cash conversion gap vs accounting profit

Operating cash flow falling short of reported profits indicates working capital volatility or non‑cash earnings items. Persistent cash conversion weakness can constrain funding for registrations and commercialization, increasing dependence on external financing during growth phases.

Eco Animal Health Business Overview & Revenue Model

Company Description

Eco Animal Health (EAH) is a global provider of innovative animal health products, specializing in sustainable solutions for livestock and aquaculture. The company focuses on developing environmentally friendly medications and nutritional products aimed at enhancing animal welfare and productivity while minimizing ecological impact. EAH operates within the veterinary pharmaceuticals sector, offering a range of products that include antimicrobial treatments, feed additives, and nutritional supplements that support the health and growth of various animal species.

How the Company Makes Money

EAH primarily makes money by selling animal health pharmaceutical products for livestock markets. Revenue is generated through (1) product sales via EAH’s own sales and distribution operations in markets where it has direct presence, and (2) sales through third-party distributors/partners in territories where EAH relies on local commercial relationships to market and distribute its products. A key driver of earnings is the commercialization of its proprietary products (including products built around active ingredients where EAH holds registrations and commercial rights), supported by regulatory approvals that enable sales in individual countries. Additional revenue can be generated where EAH enters arrangements that monetize its product portfolio through partner-led commercialization (e.g., distribution agreements); however, specific partner names, contract structures (such as royalties vs. transfer pricing), and the product-level revenue mix are null because they are not provided in the prompt.

Eco Animal Health Financial Statement Overview

Summary

Eco Animal Health demonstrates a stable financial position with a strong balance sheet and improving cash flow generation. However, inconsistent revenue growth and low net profit margins present challenges to future profitability.

Income Statement

Eco Animal Health's income statement shows a mixed performance. The company has maintained a positive gross profit margin, but it has been declining over recent years. The net profit margin is low, indicating limited profitability. Revenue growth has been inconsistent, with a notable decline in the most recent year. However, EBIT and EBITDA margins have shown some resilience, suggesting operational efficiency improvements.

Balance Sheet

The balance sheet of Eco Animal Health is relatively strong, with a low debt-to-equity ratio indicating conservative leverage. The return on equity is modest, reflecting limited profitability, but the equity ratio is healthy, suggesting a strong capital structure. Overall, the company maintains a stable financial position with manageable debt levels.

Cash Flow

Cash flow analysis reveals a positive trend in free cash flow growth, indicating improved cash generation capabilities. The operating cash flow to net income ratio is below 1, suggesting that cash flow generation is not fully aligned with accounting profits. However, the free cash flow to net income ratio is reasonable, indicating that the company is generating sufficient cash relative to its net income.

Breakdown	TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Sep 2020
Income Statement
Total Revenue	85.81M	79.60M	89.42M	85.31M	82.19M	105.61M
Gross Profit	42.10M	35.91M	37.68M	36.75M	33.70M	51.54M
EBITDA	9.60M	7.29M	6.53M	7.41M	3.62M	18.63M
Net Income	3.02M	1.69M	1.05M	1.01M	-686.00K	7.34M
Balance Sheet
Total Assets	113.96M	120.60M	123.27M	121.31M	113.60M	116.89M
Cash, Cash Equivalents and Short-Term Investments	18.64M	25.01M	22.37M	21.66M	14.31M	19.52M
Total Debt	5.06M	3.79M	4.03M	4.48M	1.91M	1.52M
Total Liabilities	21.57M	25.84M	29.89M	25.76M	19.25M	21.57M
Stockholders Equity	84.75M	85.50M	83.69M	83.27M	82.06M	81.90M
Cash Flow
Free Cash Flow	8.66M	5.44M	4.94M	10.03M	-3.25M	11.04M
Operating Cash Flow	8.99M	10.45M	9.42M	16.01M	-358.00K	12.11M
Investing Cash Flow	-5.20M	-4.61M	-3.42M	-5.98M	-2.88M	-1.06M
Financing Cash Flow	-3.33M	-1.95M	-3.69M	-2.40M	-3.31M	-684.00K

Eco Animal Health Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 78.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:EAH, the sentiment is Negative. The current price of 78.5 is below the 20-day moving average (MA) of 100.35, below the 50-day MA of 105.18, and below the 200-day MA of 87.70, indicating a neutral trend. The MACD of -2.46 indicates Positive momentum. The RSI at 39.69 is Neutral, neither overbought nor oversold. The STOCH value of 55.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:EAH.

Eco Animal Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EAH	76 Outperform	£65.39M	-44.80	3.55%	―	1.44%	359.79%
ANCR	67 Neutral	£182.28M	15.48	2.63%	2.18%	8.74%	-166.50%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Eco Animal Health Corporate Events

ECO Animal Health Wins Key USDA Safety Milestone for New Poultry Vaccine

ECO Animal Health has received a favourable safety assessment from the U.S. Department of Agriculture for ECOVAXXIN MG, its live poultry vaccine targeting the respiratory pathogen Mycoplasma gallisepticum. This review confirms that the vaccine meets stringent U.S. safety standards across chickens and other avian species and that the strain remains stable without reverting to higher virulence.

The positive risk assessment marks a key milestone toward securing U.S. marketing authorisation, with final regulatory submission expected in late 2027. Together with the anticipated 2026 commercial launch of its related ECOVAXXIN MS vaccine, the decision strengthens ECO’s poultry vaccine pipeline and supports its strategy to build a broader, innovative portfolio for global poultry producers.

The most recent analyst rating on (GB:EAH) stock is a Buy with a £105.00 price target. To see the full list of analyst forecasts on Eco Animal Health stock, see the GB:EAH Stock Forecast page.

Eco Animal Health Leaves 375,505 Shares Available Under Option Schemes

Eco Animal Health Group has provided an update on its block listing related to its Executive and Unapproved Share Option Schemes, originally covering 1.5 million ordinary shares admitted in 2017. Over the latest reporting period to 12 February 2026, no new shares were issued under these schemes, leaving 375,505 ordinary shares still available for future allotment, indicating no recent dilution for existing shareholders.

The unchanged balance under the option schemes suggests the company has maintained its current capital structure while preserving flexibility to incentivise management and employees through equity awards. This stable position in its share-based compensation arrangements comes as Eco Animal Health continues to advance its global veterinary pharmaceuticals business and develop its proprietary pipeline, which is central to its long-term growth strategy.

The most recent analyst rating on (GB:EAH) stock is a Hold with a £114.00 price target. To see the full list of analyst forecasts on Eco Animal Health stock, see the GB:EAH Stock Forecast page.

ECO Animal Health sets EU launch plan for new poultry vaccine ECOVAXXIN MS

ECO Animal Health Group has outlined its EU commercial launch strategy for ECOVAXXIN® MS, a poultry vaccine targeting Mycoplasma synoviae in layer and breeder chickens, following European Commission marketing authorisation granted in late 2025. The product, which reduces lesions and egg production losses, positions the company as a full Mycoplasma solutions provider alongside its established treatment Aivlosin®.

The group will leverage its existing EU commercial network and newly signed strategic distribution partnerships to cover major poultry markets representing more than 220 million layer birds annually. A phased rollout, including distributor training, a Madrid launch event in mid-2026, and regional launches through early 2027, is expected to make ECOVAXXIN® MS immediately margin accretive and to deliver a material EBITDA contribution in the 2027/28 financial year, strengthening ECO’s competitive position in the poultry health segment.

The most recent analyst rating on (GB:EAH) stock is a Hold with a £114.00 price target. To see the full list of analyst forecasts on Eco Animal Health stock, see the GB:EAH Stock Forecast page.

ECO Animal Health Wins Early EU Approval for New Poultry Vaccine

ECO Animal Health Group has secured European Union marketing authorisation for ECOVAXXIN MS, its new poultry vaccine targeting Mycoplasma synoviae, more than a month earlier than expected. The approval marks the first commercial launch from the company’s innovative R&D portfolio and is a strategic milestone that strengthens its position in the poultry health segment, addressing a disease that can cut egg production by 5–10% and cause significant economic losses for layer and breeder operations; ECO plans to outline its EU commercial launch strategy for the vaccine in early 2026.

The most recent analyst rating on (GB:EAH) stock is a Buy with a £123.00 price target. To see the full list of analyst forecasts on Eco Animal Health stock, see the GB:EAH Stock Forecast page.